This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Canadian Collaborative Research Network Identifier:
First received: November 2, 2012
Last updated: October 11, 2016
Last verified: October 2016
This observational registry will characterize contemporary stroke prevention in Canadian adults with atrial fibrillation, and provide clarity in understanding physician preferences for the various oral anticoagulants available in the Canadian marketplace. This study will determine the patient profiles of those selected for the various therapies available in Canada and provide an understanding of the factors involved in drug selection and management.

Cardiovascular Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by Canadian Collaborative Research Network:

Primary Outcome Measures:
  • To determine how Canadian physicians assess stroke risk in adults with atrial fibrillation and make therapeutic decisions around anticoagulation [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • To assess the adequacy of anticoagulation in treated patients [ Time Frame: 1 year ]
  • To understand how new oral anticoagulants are incorporated into clinical practice [ Time Frame: 1 year ]
  • To assess quality of life in patients with AF [ Time Frame: 1 year ]
  • To evaluate how physicians select between rate and rhythm control options for AF [ Time Frame: 1 year ]
  • To evaluate regional differences in care [ Time Frame: 1 year ]
  • To compare management strategies between primary care physicians and cardiovascular specialists [ Time Frame: 1 year ]

Enrollment: 2499
Study Start Date: November 2013
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care and specialist clinics

Inclusion Criteria:

  • Documented atrial fibrillation (ECG, rhythm strip, device interrogation, discussion of an AF diagnosis in the participant's clinical report) within the past 10 years; paroxysmal, persistent or permanent
  • Age > 18 years
  • Most recent visit for a patient having had a clinical visit with Investigator occurring within the past one year

Exclusion Criteria:

  • Valvular AF (hemodynamically significant valvular heart disease including rheumatic mitral valve disease or at least moderate aortic valve stenosis)
  • Life expectancy < 12 months
  • Active malignancy (treated or untreated)
  • Indication for systemic anticoagulation independent of atrial fibrillation (venous thromboembolism, mechanical heart valve)
  • Prior participation in any OAC randomized clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01733160

Canada, Ontario
Brampton, Ontario, Canada, L6Z 4N5
Sponsors and Collaborators
Canadian Collaborative Research Network
Principal Investigator: Milan K Gupta, MD Canadian Collaborative Research Network
Principal Investigator: Andrew Ha, MD Canadian Collaborative Research Network
  More Information

Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15;123(10):1144-50. doi: 10.1161/CIR.0b013e31820f14c0. Epub 2011 Feb 14.

Responsible Party: Canadian Collaborative Research Network Identifier: NCT01733160     History of Changes
Other Study ID Numbers: SPRINT-AF 18-10-2012
Study First Received: November 2, 2012
Last Updated: October 11, 2016

Keywords provided by Canadian Collaborative Research Network:
Atrial Fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes processed this record on July 19, 2017